Continuing Education


At the completion of this activity participants should be able to:

  • Discuss new emerging hematology therapies in general and for chronic Myeloid Leukemia, acute Promylelocytic and Myeloid Leukemia, and Myeloproliferative disorders.
  • Recognize molecular diagnosis, targeted therapies, and resistance mechanisms of Waldenström’s Macroglobulinemia to assist in disease recognition.
  • Discuss the advancement of immune check point inhibitors within hematologic malignancies and updated treatment paradigms presented at the American Society of Hematology meeting in Atlanta, Georgia in December 2017.
  • Identify new regimens for Hematopoietic Stem Cell transplantation and identification of transplant candidates.
  • Review the advancement in benign hematology research.
  • Review new treatment regimens in chronic Lymphocytic Leukemia.


CME Accreditation Statement: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Indiana Association of Pathologists and Indy Hematology Education, Inc. The Indiana Association of Pathologists is accredited by the Indiana State Medical Association to provide continuing medical education for physicians.

Designation Statement: The Indiana Association of Pathologists designates this live activity for a maximum of 8.5 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Statement: In accordance with the ACCME Standards for Commercial Support, educational programs sponsored by the Indiana Association of Pathologists (IAP) must demonstrate balance, independence, objectivity, and scientific rigor. Prior to the activity, all faculty, authors, editors, and planning committee members participating in an IAP-sponsored activity are required to disclose to attendees any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

Note: While it offers CME credits, this activity is not intended to provide extensive training or certification in the field.


CNE Accreditation Statement: This continuing nursing education activity was approved by the Ohio Nurses Association (OBN-001-91), an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

Assigned ONA #21199
This program is approved for 7.75 contact hours.


ACPECPE Accreditation Statement: Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge based, continuing education activity of Purdue University, an equal access/equal opportunity institution.

Universal Activity Number (UAN): 0018-9999-18-001-L01-P
This program is approved for 7.75 contact hours (0.775 CEU’s).